CRIS Current Research Information System

GRAMENZI, ANNAGIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.137
AS - Asia 4.158
EU - Europa 4.120
AF - Africa 346
SA - Sud America 277
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.047
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.098
SG - Singapore 1.299
CN - Cina 1.112
GB - Regno Unito 1.003
VN - Vietnam 922
SE - Svezia 630
IT - Italia 613
DE - Germania 526
HK - Hong Kong 300
IN - India 231
RU - Federazione Russa 216
BR - Brasile 193
UA - Ucraina 180
FR - Francia 175
IE - Irlanda 169
NL - Olanda 143
CH - Svizzera 126
TG - Togo 114
KR - Corea 94
ZA - Sudafrica 86
CI - Costa d'Avorio 78
EE - Estonia 74
JO - Giordania 70
FI - Finlandia 69
BG - Bulgaria 53
JP - Giappone 45
BE - Belgio 39
SC - Seychelles 33
AR - Argentina 28
IR - Iran 24
CA - Canada 22
EC - Ecuador 21
GR - Grecia 21
NG - Nigeria 18
HR - Croazia 17
ID - Indonesia 15
CL - Cile 13
ES - Italia 12
PL - Polonia 12
AT - Austria 11
MX - Messico 9
BD - Bangladesh 8
LB - Libano 8
CO - Colombia 7
UZ - Uzbekistan 7
PT - Portogallo 6
MA - Marocco 5
AU - Australia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
LT - Lituania 4
MY - Malesia 4
PY - Paraguay 4
RO - Romania 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
EG - Egitto 3
KZ - Kazakistan 3
MK - Macedonia 3
PE - Perù 3
PK - Pakistan 3
TR - Turchia 3
UY - Uruguay 3
ET - Etiopia 2
IQ - Iraq 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CV - Capo Verde 1
DM - Dominica 1
DZ - Algeria 1
EU - Europa 1
GL - Groenlandia 1
LU - Lussemburgo 1
LV - Lettonia 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
PW - Palau 1
SA - Arabia Saudita 1
SN - Senegal 1
SV - El Salvador 1
TN - Tunisia 1
YE - Yemen 1
YT - Mayotte 1
Totale 15.047
Salva come PNG Salva come JPEG
Città #
Southend 879
Singapore 861
Fairfield 750
Ashburn 638
Chandler 532
Woodbridge 334
Dong Ket 326
Houston 326
Hong Kong 300
Seattle 282
Wilmington 267
Cambridge 242
Ann Arbor 229
Santa Clara 226
Princeton 213
Hefei 180
Bologna 171
Dublin 169
Ho Chi Minh City 161
Beijing 159
Boardman 140
Hanoi 122
Bern 116
Lomé 114
Jacksonville 109
Seoul 88
Westminster 88
Dallas 81
Abidjan 78
Padova 77
Nanjing 75
Los Angeles 74
Amman 70
Berlin 60
New York 58
Redmond 57
Shenyang 50
Sofia 50
Helsinki 49
Jinan 49
Milan 47
Munich 46
Saint Petersburg 45
Tokyo 44
San Diego 42
Buffalo 40
Brussels 39
Florence 37
Turin 36
Changsha 34
Redondo Beach 29
Frankfurt am Main 28
Bremen 27
Medford 26
Council Bluffs 25
Nanchang 24
Tianjin 24
Dearborn 23
São Paulo 23
Haiphong 22
Hebei 22
Falkenstein 21
Guangzhou 20
Phoenix 20
Des Moines 19
Jiaxing 19
Mülheim 19
Paris 19
Abeokuta 18
Bengaluru 18
London 18
Norwalk 18
Shanghai 17
Zhengzhou 17
Da Nang 16
Falls Church 16
Hangzhou 16
Mahé 16
Turku 16
Chicago 15
Wuhan 15
Redwood City 13
Rome 13
Thái Nguyên 13
Ha Long 12
Olalla 12
Orem 12
Quận Bình Thạnh 12
Ningbo 11
San Francisco 11
Guayaquil 10
Hyderabad 10
Hải Dương 10
Nuremberg 10
Washington 10
Yubileyny 10
Amsterdam 9
Brooklyn 9
Can Tho 9
Las Vegas 9
Totale 10.091
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 488
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 265
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 237
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 230
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 222
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 214
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 208
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 208
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 204
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 203
Computed Tomography-Colonography With Intravenous Contrast Medium and Urographic Phase for the Evaluation of Pelvic Deep Infiltrating Endometriosis of Intestinal and Urinary Tract 199
Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma 195
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 194
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 194
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 192
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 192
Monofocal hepatocellular carcinoma: How much does size matter? 189
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 183
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 182
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 181
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. 179
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 178
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 176
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 174
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 174
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 172
Vitamins in the treatment of chronic viral hepatitis. 169
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 168
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 166
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 166
null 164
Metabolic disorders across hepatocellular carcinoma in Italy 163
Pattern of macrovascular invasion in hepatocellular carcinoma 159
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 158
Liver transplantation for patients with alcoholic liver disease: an open question 158
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 155
Hepatitis B virus and immune response. 154
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 154
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 154
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 152
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 149
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 147
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 146
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. 146
Stem cell mobilization and collection in patients with liver cirrhosis. 144
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 144
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 143
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 143
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 143
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 142
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. 140
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 137
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 135
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 135
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 134
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 133
Years of life that could be saved from prevention of hepatocellular carcinoma. 133
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 132
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 132
Probiotics History. 131
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 130
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 130
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 130
Ketoprofen, peginterferon-alpha2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 129
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 126
Redefinition of diagnostic role of inferior vena cava ultrasonography in the identification of acute heart failure. 124
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 121
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 121
Reply to: "Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?" 121
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 117
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 117
null 117
Vitamin E as treatment for chronic viral hepatitis: is it time to perform large clinical trials? 113
The changing scenario of hepatocellular carcinoma in Italy: an update 112
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 112
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 111
TRANS-ARTERIAL RADIOEMBOLIZATION FOR INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: A BUDGET IMPACT ANALYSIS 111
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 110
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 110
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 110
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 107
La radioembolizzazione nel trattamento del colangiocarcinoma intraepatico inoperabile: efficacia, sopravvivenza e sicurezza 107
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 106
Hepatitis C in the elderly: a multicenter cross-sectional study by the Italian Association for the Study of the Liver. 100
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 97
Capitolo 14 "Epatiti Virali Croniche", Volume IX "Malattie del Fegato, delle Vie Biliari e del Pancreas", Trattato di Medicina Interna, fondato da Paolo Larizza 94
Post-transplantation lymphoproliferative disorders in liver transplanted patients: a report of four cases 89
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 87
Fegato e infezioni sistemiche. 85
null 83
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 81
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 80
Role of CT colonography (CTC) in a regional colorectal cancer (CRC) screening programme: preliminary results. 78
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 75
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 74
null 73
null 72
null 70
Radioembolizzazione con 90Y versus sorafenib nei pazienti cirrotici con carcinoma epatocellulare (HCC): studio monocentrico con analisi di propensity 70
Totale 14.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.003 0 0 0 0 0 64 32 69 164 73 81 520
2021/20222.147 157 86 121 202 170 121 56 134 63 166 550 321
2022/20232.379 231 364 112 314 120 189 87 119 398 80 189 176
2023/2024628 51 95 40 56 59 150 17 45 29 31 23 32
2024/20252.330 89 362 193 189 350 142 178 59 16 167 127 458
2025/20262.819 709 431 504 336 550 289 0 0 0 0 0 0
Totale 15.277